IJE Advance Access published online on July 15, 2004
International Journal of Epidemiology, doi:10.1093/ije/dyh251
© 2004 by International Epidemiological Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Public Health Sciences, University of Toronto, Toronto; Department of Nutritional Sciences, University of Toronto, Toronto
* To whom correspondence should be addressed. E-mail: gail.eyssen{at}utoronto.ca.
Background Impaired metabolism of toxic chemicals is a postulated mechanism underlying multiple chemical sensitivity (MCS). Because genetic variation alters the rate of chemical metabolism, this study was designed to determine if MCS cases differed from controls for genetic polymorphisms in drug-metabolizing enzymes. Methods Female Caucasian participants (203 cases and 162 controls) were drawn from a larger case-control study based on a reproducible and validated case definition. Common polymorphisms for CYP2D6, NAT1, NAT2, PON1, and PON2 were genotyped. Results Comparing cases and controls, significant differences were found in genotype distributions for CYP2D6 (P = 0.02) and NAT2 (P = 0.03). Compared with the referent homozygous inactive (CYP2D6) or slow (NAT2) metabolizers, the odds for being CYP2D6 homozygous active (OR = 3.36, P = 0.01) and NAT2 rapid (OR = 4.14, P = 0.01) were significantly higher in cases than controls. The odds for being heterozygous for PON1-55 (OR = 2.05, P = 0.04) and PON1-192 (OR = 1.57, P = 0.04) were also significantly higher in cases. Conclusions A genetic predisposition for MCS may involve altered biotransformation of environmental chemicals. The CYP2D6 enzyme activates and inactivates toxins; the NAT2 enzyme bioactivates arylamines to protein-binding metabolites. A gene-gene interaction between CYP2D6 and NAT2 suggested that rapid metabolism for both enzymes may confer substantially elevated risk (OR = 18.7, P = 0.002). Our finding parallels others' observation of a link between PON1 heterozygosity and neurological symptoms in Gulf War syndrome. This first demonstration of genetic variation in drug-metabolizing enzymes in association with MCS requires replication. However, it suggests new research directions on genetically variable toxin pathways that might be important in MCS.
Original paper
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR
2 Department of Public Health Sciences, University of Toronto, Toronto
3 Department of Laboratory Medicine and Pathology, University of Toronto, Toronto; Department of Medicine, University of Toronto, Toronto; Department of Pediatrics (Genetics), University of Toronto, Toronto
4 Centre for Addiction and Mental Health, Toronto; Department of Pharmacology, University of Toronto, Toronto
5 Environmental Health Clinic Unit, Women's College Hospital Toronto, Toronto; Ambulatory Care Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Iribarren, P. Prolo, N. Neagos, and F. Chiappelli Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium Evid. Based Complement. Altern. Med., December 1, 2005; 2(4): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J Palmer The New Epidemiology: putting the pieces together in complex disease aetiology Int. J. Epidemiol., October 1, 2004; 33(5): 925 - 928. [Full Text] [PDF]
|
|